Merck & Company Inc is trading 5.1% up at $120.52, benefiting from positive pipeline developments and a broader market shift into defensive and healthcare stocks.
- Positive Pipeline News: Recent FDA 'Breakthrough Therapy' designation for a lung cancer drug combination and strong data for its melanoma therapy, developed with Moderna, have bolstered investor confidence.
- Strong Analyst Sentiment: Multiple analysts have reiterated "Buy" or "Moderate Buy" ratings in early June, with an average price target suggesting further upside.
- Market Rotation: The stock is also being lifted by a market-wide rotation into defensive sectors like healthcare as investors move away from growth-oriented equities.